Compugen Launches Gencarta Annotated Genome, Transcriptome and Proteome Database Over the Web.Business Editors & Health/Medical Writers BIOWIRE2K Drug Discovery Expo 2002 (the Center Stage of the Exhibit Hall) BOSTON--(BW HealthWire)--Aug. 5, 2002 Compugen Ltd. (Nasdaq:CGEN CGEN Convective Sigmet Generation ) presented Gencarta(TM) over the Web today at the Drug Discovery Technology conference. Gencarta, introduced in March 2001, is a comprehensive annotated genome, transcriptome The transcriptome is the set of all messenger RNA (mRNA) molecules, or "transcripts", produced in one or a population of cells. The term can be applied to the total set of transcripts in a given organism, or to the specific subset of transcripts present in a particular cell type. and proteome pro·te·ome n. The complete set of proteins that are produced by the genes of an organism. proteome the entire complement of proteins produced by a cell. database accessed through an intuitive viewer and a flexible query engine for advanced post-genomic research. The availability of the database over the Web will make it more accessible to life science researchers worldwide. "We are delighted to announce that Gencarta is now commercially available over the Web," said Erez Chimovits, Compugen's Executive Vice President, Marketing and Sales. "Following the initial success of this product, we decided to expand our licensing options to include an over the Web subscription offering in addition to installations at users' sites. Gencarta over the Web addresses scientists' needs for one reliable annotated data source that can be rapidly accessed and easily queried." Gencarta, a valuable research tool for the enhancement of drug discovery, is created utilizing Compugen's LEADS platform. Using advanced algorithms, LEADS analyzes publicly available nucleotide and protein sequence data, as well as other data sources. Many of the Gencarta predictions were validated by laboratory experiments. Gencarta annotated database turns raw expressed and genomic data into meaningful information by providing accurate modeling of complex biological phenomena, in particular alternative splicing Alternative splicing is the RNA splicing variation mechanism in which the exons of the primary gene transcript, the pre-mRNA, are separated and reconnected so as to produce alternative ribonucleotide arrangements. , the creation of more than one protein from a single gene. The database thus provides a comprehensive view of the transcriptome, the biological bridge between the genome and its encoded proteins. Novel genes, splice variants and predicted proteins, along with Gene Ontology The Gene Ontology project, or GO, provides a controlled vocabulary to describe gene and gene product attributes in any organism. It can be broadly split into two parts. annotations, predicted SNPs, expression profiles and protein homologies are all part of the product offering. Gencarta over the Web is available at www.gencarta.com. Come see Compugen's Gencarta product demonstration at Drug Discovery Technology, The Hynes Convention Center The John B. Hynes Veterans Memorial Convention Center located in Boston's Back Bay has 193,000 square feet (0 m) of exhibit space and can accommodate up to four concurrent events. , Boston on August 7th at 2:30 pm, at the Center Stage of the Exhibit Hall. About Compugen Compugen (Nasdaq:CGEN) is a pioneer in the merging of computational technologies with biology, chemistry and medicine to enhance drug discovery and development. This unique capability is a proven basis for providing high value products and services to leading biotechnology and pharmaceutical companies and for in-house discovery. For additional information, please visit Compugen's Corporate Website at www.cgen.com and the Company's Internet research This article is about using the Internet for research; for the field of research about the Internet, see Internet studies. Internet research is the practice of using the Internet, especially the World Wide Web, for research. engine for molecular biologists, www.LabOnWeb.com. This press release contains "forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. " within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These statements include words like "may," "expects," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc the development of new products; the ability to implement technological improvements; the ability of Compugen to obtain and retain customers. These and other factors are identified and more fully explained under the heading "Risk Factors" in Compugen's Registration Statement on Form F-1 and its annual reports filed with the Securities and Exchange Commission. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion